tailieunhanh - Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: An open-label, multicenter phase I study

Melanoma is a rare, deadly disease without effective treatment options in China. Vemurafenib is a selective inhibitor of oncogenic BRAFV600 kinase approved in more than 90 countries, based on results obtained primarily in Caucasian patients. | Vemurafenib in Chinese patients with BRAFV600 mutation positive unresectable or metastatic melanoma An open-label multicenter phase I study

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN